Loading provider…
Loading provider…
Hematology & Oncology Physician in Milwaukee, WI
NPI: 1386668192Primary Practice Location
FROEDTERT MEMORIAL LUTHERAN HOSPITAL
900 N 92nd St, Milwaukee, WI
Primary Employer
The Medical College of Wisconsin, Inc.
mcw.edu
HQ Phone
Get M.D. John's Phone NumberMobile
Get M.D. John's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardWI State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 61 | 89 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 50 | 144 |
| 3 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 25 | 72 |
| 4 | 99215Established patient office or other outpatient, visit typically 40 minutes | 25 | 42 |
| 5 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 17 | 57 |
Authors: David King, Adam Wooldridge, John Neilson, Candice Johnstone, Tracy Kelly, Donald Hackbarth
Journal: Adv Radiat Oncol
Publication Date: 2022-01-25
Authors: Mohammed Milhem, Varun Monga, Angela Hirbe, Brian Schulte, Nisha Mohindra, Steven Robinson, Scott Okuno, Mark Agulnik, Peter Oppelt
Journal: Br J Cancer
Publication Date: 2021-05-28
Lead Sponsor: City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Questionnaire Administration, DRUG: Temozolomide, OTHER: Quality-of-Life Assessment, DRUG: Cabozantinib
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, OTHER: Questionnaire Administration, BIOLOGICAL: Nivolumab, PROCEDURE: Biospecimen Collection, OTHER: Quality-of-Life Assessment, DRUG: Paclitaxel, PROCEDURE: Computed Tomography, DRUG: Cabozantinib S-malate, PROCEDURE: FDG-Positron Emission Tomography
Lead Sponsor: Adaptimmune
Collaborators: ICON plc
Intervention / Treatment: GENETIC: Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks